TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today additional details regarding its first Analyst & Investor Day on Thursday, April 11, 2019. The event will be held at the University Club in New York, NY. The agenda will commence at 9:30 a.m. and is scheduled to conclude at approximately 2:00 p.m. Eastern Time.
The program will feature presentations on TULSA-PRO® from key opinion leaders in the United States who have gained first-hand experience with the technology as investigators for the TACT trial and from current commercial users in Europe. In addition, leading global researchers and clinicians will present on both current and potential future applications for Sonalleve®.
Agenda:
| TIME | SPEAKER | DETAILS |
| 9:30 – 10:00 a.m. | Product Demos & Networking | |
| 10:00 – 10:10 a.m. | Arun Menawat, PhD, Profound Medical | Welcome & Introduction |
| 10:10 – 10:35 a.m. | Mathieu Burtnyk, PhD, Profound Medical | TULSA Technology & Clinical Data |
| 10:35 – 10:55 a.m. | Dr. Christian Pavlovich, Johns Hopkins | TACT Study Experience, Perspectives & Outlook |
| 10:55 – 11:05 a.m. | Dr. Laurence Klotz, Sunnybroook HSC | New Evolution in Localized Prostate Cancer Management |
| 11:05 – 11:15 a.m. | Dr.Steven Raman, UCLA | MRI Paradigm Shift in Prostate Cancer: Diagnosis, Treatment and Follow-up |
| 11:15 – 11:35 a.m. | Dr. Agron Lumiani, ALTA Clinic | TULSA in the Clinic: Real World Experience and Outcomes |
| 11:35 – 11:50 a.m. | Dr. Peter Boström, Turku University | TULSA Customization & Flexibility: Ablation of Multiple Prostate Diseases |
| 11:50 – 12:05 p.m. | Arun Menawat | TULSA-PRO® Value |
| 12:05 – 12:20 p.m. | Holger Grüll, PhD, University Hospital Cologne | Sonalleve® Platform Technology & Current and Future Clinical Applications |
| 12:20 – 12:35 p.m. | Dr. Karun Sharma, George Washington University | Sonalleve® MRI-Guided HIFU in the Treatment of Pediatric Diseases |
| 12:35 – 12:40 p.m. | Arun Menawat | Closing Remarks |
| 1:00 – 2:00 p.m. | Dr. Neal Kassell, Focused Ultrasound Foundation | Lunch – Key Note Speaker |
Advance registration is required for the event and space is limited. Those wishing to attend the live event should register online at www.profoundmedical.com/analystmeeting2019.
For individuals who are unable to attend the meeting in person, a live webcast will be available on the Company’s website at www.profoundmedical.com under "Webcasts" in the Investor Relations section.
About Profound Medical Corp.
Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.
TULSA-PRO® is CE marked and commercially launched in key European and other CE mark jurisdictions. TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”).
Profound has completed enrollment and 12-month follow-up in a multicenter, prospective clinical trial, TACT, which is expected to support its application to the U.S. FDA for approval to market TULSA-PRO® in the United States.
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849